Trial Profile
An Open-Label, Multiple-Dose, Randomized, 2-Way Crossover Study In Healthy Volunteers To Determine The Steady-State Pharmacokinetics Of The 82.5 Mg Pregabalin Controlled Release Formulation Administered Following An Evening Meal Relative To The 25 Mg Of The Immediate Release Formulation Administered Three Times Daily.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Jan 2021
Price :
$35
*
At a glance
- Drugs Pregabalin (Primary)
- Indications Fibromyalgia; Generalised anxiety disorder; Neuropathic pain; Partial epilepsies; Postherpetic neuralgia; Postoperative pain; Tonic-clonic epilepsy
- Focus Pharmacokinetics
- Sponsors Pfizer
- 06 Dec 2010 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
- 06 Dec 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Nov 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.